低分子肝素钙和利伐沙班联合阿托伐他汀对急性肺栓塞患者相关指标的影响
发布时间：2019-06-04 04:07
【摘要】：目的:探讨低分子肝素钙和利伐沙班联合阿托伐他汀对急性肺栓塞患者相关指标的影响。方法:回顾性分析72例急性肺栓塞患者资料,根据治疗方案的不同分为A组(21例)、B组(26例)和C组(25例)。A组患者入院后立即肌内注射低分子肝素钙注射液2 d后加用华法林钠片,7 d后停用低分子肝素钙注射液,继续服用华法林3~6个月。B组患者给予低分子肝素钙注射液(用法用量同A组),2 d后加用利伐沙班片7 d后停用低分子肝素钙注射液,继续服用利伐沙班3~6个月。C组患者在B组治疗的基础上给予阿托伐他汀钙片,持续3~6个月。观察3组患者呼吸困难、胸痛、发绀消失时间,治疗前后心率(HR)、动脉血氧分压[pa(O2)]、动脉血二氧化碳分压[pa(CO2)]、C反应蛋白(CRP)、D-二聚体(D-D)、肿瘤坏死因子α(TNF-α)、白细胞介素1(IL-1)、IL-6、内皮素1(ET-1)、一氧化氮(NO)水平,临床终点事件发生情况和不良反应发生情况。结果:患者呼吸困难、胸痛、发绀消失时间A组B组C组,差异均有统计学意义(P0.05)。治疗前,3组患者HR、pa(O2)、pa(CO2)、CRP、IL-1、IL-6、TNF-α、DD、ET-1、NO水平比较,差异均无统计学意义(P0.05)。治疗后,3组患者HR均显著低于同组治疗前,且A组B组C组;3组患者pa(O2)、pa(CO2)均显著高于同组治疗前,且A组B组C组,组间比较差异均有统计学意义(P0.05)。治疗后,3组患者CRP、IL-1、IL-6、TNF-α、D-D水平均显著低于同组治疗前,且C组A、B组,差异均有统计学意义(P0.05);但A、B组比较,差异均无统计学意义(P0.05)。治疗后,3组患者ET-1水平均显著低于同组治疗前,且C组B组A组;3组患者NO水平均显著高于同组治疗前,且C组B组A组,差异均有统计学意义(P0.05)。C组患者临床终点事件发生率显著低于A组,B组患者不良反应发生率显著低于A组,差异均有统计学意义(P0.05)。结论 :低分子肝素钙和利伐沙班联合阿托伐他汀可显著改善急性肺栓塞患者的临床症状、血气指标,减轻血管内皮受损程度,降低细胞因子水平,改善预后,且未增加不良反应的发生。
[Abstract]:Objective: to investigate the effects of low molecular weight heparin calcium (LMWH) and rivashaban combined with Atto statins on the related indexes of patients with acute pulmonary embolism. Methods: the data of 72 patients with acute pulmonary embolism were analyzed retrospectively. according to the different treatment schemes, they were divided into group A (21 cases). Group B (26 cases) and group C (25 patients in). A group) were treated with low molecular weight heparin calcium injection 2 days after admission and low molecular weight heparin calcium injection 7 days later. Patients in group B were given low molecular weight heparin calcium injection (the same dosage as group A), and 2 days later, rivasaban tablets were added for 7 days and then low molecular weight heparin calcium injection was stopped. Patients in group C were given Atto Vastatin calcium tablets on the basis of treatment in group B for 3 to 6 months. To observe the disappearance time of dyspnea, chest pain and cyanosis in the three groups, heart rate (HR), arterial partial pressure of oxygen [pa (O2)], arterial partial pressure of carbon dioxide [pa (CO2)] and C-reactive protein (CRP), before and after treatment. D-dimer (D 鈮，
本文编号：2492461
[Abstract]:Objective: to investigate the effects of low molecular weight heparin calcium (LMWH) and rivashaban combined with Atto statins on the related indexes of patients with acute pulmonary embolism. Methods: the data of 72 patients with acute pulmonary embolism were analyzed retrospectively. according to the different treatment schemes, they were divided into group A (21 cases). Group B (26 cases) and group C (25 patients in). A group) were treated with low molecular weight heparin calcium injection 2 days after admission and low molecular weight heparin calcium injection 7 days later. Patients in group B were given low molecular weight heparin calcium injection (the same dosage as group A), and 2 days later, rivasaban tablets were added for 7 days and then low molecular weight heparin calcium injection was stopped. Patients in group C were given Atto Vastatin calcium tablets on the basis of treatment in group B for 3 to 6 months. To observe the disappearance time of dyspnea, chest pain and cyanosis in the three groups, heart rate (HR), arterial partial pressure of oxygen [pa (O2)], arterial partial pressure of carbon dioxide [pa (CO2)] and C-reactive protein (CRP), before and after treatment. D-dimer (D 鈮，
本文编号：2492461
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2492461.html
最近更新
教材专著
